KalVista Pharmaceuticals, Inc.
KalVista Pharmaceuticals, Inc. (KALV) PE Ratio — Current & Historical Data
Trailing twelve months (TTM) P/E, forward P/E, PEG, and annual PE history — from market prices and filings.
kalv · pe ratio · data through Dec 31, 2025
Core PE Ratio Metrics
Trailing 12 months · TTMThe price-to-earnings (P/E) ratio for KalVista Pharmaceuticals, Inc. (KALV) measures how much investors pay for each dollar of the company's trailing earnings. KALV's current PE ratio of N/A is calculated by dividing its stock price of $26.95 by its TTM earnings per share of -$2.74.
Source: FMP · /ratios-ttm · /analyst-estimates · 2025-12-31
PE Ratio History
2012 – 2025 · Annual▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare (Annual)
PE Ratio vs Peers
Biotechnology · 6 peers · Annual PE| Company | Market Cap | PE (Annual) | vs Avg | EPS (TTM) |
|---|---|---|---|---|
KalVista Pharmaceuticals, Inc.You KALV | $1.4B | N/A | — | -$2.74 |
 ADC Therapeutics S.A. ADCT | $131M | N/A | — | -$1.12 |
 Bicycle Therapeutics plc BCYC | $291M | N/A | — | -$3.16 |
 4D Molecular Therapeutics, Inc. FDMT | $452M | N/A | — | -$2.42 |
 Gossamer Bio, Inc. GOSS | $41M | N/A | — | -$0.75 |
 Olema Pharmaceuticals, Inc. OLMA | $901M | N/A | — | -$1.87 |
 Omeros Corporation OMER | $709M | N/A | — | -$0.05 |
* N/A — Company is not profitable (TTM) · excluded from industry average · ▸ FMP /stock-peers + /ratios?limit=1 · priceToEarningsRatio
Annual PE Ratio History
| Fiscal Year End | PE Ratio | EPS (TTM) | YoY Change | PE vs Max |
|---|---|---|---|---|
2025-12-31Latest FY2025 | — | $-3.23 | — | |
2025-04-30 FY2025 | — | $-3.69 | — | |
2024-04-30 FY2024 | — | $-3.44 | — | |
2023-04-30 FY2023 | — | $-3.33 | — | |
2022-04-30 FY2022 | — | $-3.36 | — | |
2021-04-30 FY2021 | — | $-2.42 | — | |
2020-04-30 FY2020 | — | $-1.64 | — | |
2019-04-30 FY2019 | — | $-1.38 | — | |
2018-04-30 FY2018 | — | $-1.53 | — | |
2017-04-30 FY2017 | — | $-1.92 | — |
▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare · Zero extra API
About PE Ratio & Methodology
The price-to-earnings (P/E) ratio for KalVista Pharmaceuticals, Inc. (KALV) measures how much investors pay for each dollar of the company's trailing earnings. KALV's current PE ratio of N/A is calculated by dividing its stock price of $26.95 by its TTM earnings per share of -$2.74.
Frequently asked questions
KALV pe ratio · 6 questionsKALV's current PE ratio is N/A as of 2026-06-08, based on a stock price of $26.95 and TTM EPS of -$2.74. Data sourced from Financial Modeling Prep via KALV's SEC 10-K and 10-Q filings.
▸ Source: FMP · /ratios-ttm · /ratios annual · /analyst-estimates · /stock-peers · KalVista Pharmaceuticals, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: 2026-06-08